Trial Profile
DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms REMARC
- 18 Dec 2021 This trial has been completed in Poland, according to European Clinical trial database
- 16 Dec 2021 This trial has been completed in France, according to European Clinical trial database
- 08 Dec 2020 Results of final analysis of the REMARC study, assessing the benefit of lenalidomide maintenance in response after R-CHOP, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology